AzTrials
AzTrials

Aortic Valve StenosisGUIDE-SAVRNCT06603454

Preoperative Chest CT-imaging in Surgical Aortic Valve Replacement with or Without CABG

A study testing Preoperative CT in people with Aortic Valve Stenosis, run by Romy Hegeman at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Rationale When determining the strategy for aortic valve replacement, echocardiography is still considered the golden standard (1). While pre-procedural MSCT is standard of care in TAVR patients, this is not yet part of routine clinical practice in SAVR patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Aortic Valve Stenosis
What is being tested?
Preoperative CT
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
380 participants
Where
1 siteNetherlands
Study dates
4 Dec 2023to 1 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Primary symptomatic severe aortic valve stenosis (defined as an aortic valve area of <1.0cm2 and either a mean valve gradient of at least 40mmHg or a peak velocity of at least 4.0 m/s)
  • Accepted for SAVR (either planned to be done by a limited access approach (partial J-shaped sternotomy or right anterior thoracotomy or conventional median sternotomy approach at the preference of the patient and/or the discretion of the surgeon) with or without concomitant CABG by the Heart Team
  • Informed consent

Who cannot join

  • Previous aortic valve replacement
  • Emergency procedure
  • Pregnant women
  • Renal failure (eGFR <30 ml/min.)
  • Known contrast allergy
  • Patient unwilling to be informed about unrequested findings on the CT scan or DW-MRI scan
Show all 9Show fewer
  • Contra-indication for MRI (e.g. permanent pacemaker or ICD that can not be inactivated per order of the pacemaker or ICD technician, morphine or insulin pump, neurostimulator). All patients will fill out a MRI checklist to additionally check for (new) safety contra-indications for MRI.
  • Patient who did not agree to the informed consent and/or refused to participate
  • Patient unable to understand the informed consent/study

Trial locations and contacts

1 site in 1 country.

Netherlands1 site, 1 recruiting
  • St. Antonius Hospital

    Nieuwegein, Utrecht, 3435 CM

    Romy Hegeman, MD, +31 (0)6 41 71 16 79, r.hegeman@antoniusziekenhuis.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: Preoperative Chest CT-imaging in Surgical Aortic Valve Replacement with or Without CABG: a Randomized Controlled Trial

Rationale When determining the strategy for aortic valve replacement, echocardiography is still considered the golden standard (1). While pre-procedural MSCT is standard of care in TAVR patients, this is not yet part of routine clinical practice in SAVR patients. The researchers hypothesise that when atherosclerosis of the ascending aorta is identified preoperatively on contrast-enhanced multi-slice computed tomography (MSCT), the subclinical perioperative stroke rate (as detected on diffusion-weighted magnetic resonance imaging (DW-MRI)) can be reduced by modification of the operative strategy if necessary.

Read the detailed description

When determining the strategy for aortic valve replacement, echocardiography is still considered the golden standard (1). While pre-procedural MSCT is standard of care in TAVR patients, this is not yet part of routine clinical practice in SAVR patients. The investigators hypothesise that when atherosclerosis of the ascending aorta is identified preoperatively on contrast-enhanced multi-slice computed tomography (MSCT), the subclinical perioperative stroke rate (as detected on diffusion-weighted magnetic resonance imaging (DW-MRI)) can be reduced by modification of the operative strategy if necessary.

The primary objective is to assess whether the use of pre-operative MSCT will reduce subclinical stroke rates (i.e., ischemic brain lesions) as identified with the use of DW-MRI after SAVR with or without concomitant CABG surgery.

The secondary objective is to assess whether the use of pre-operative MSCT will improve neurological assessment score, reduce clinical stroke, mortality, change in intervention strategy (pre- or intra-operatively), cannulation strategy and clamping strategy as well as reduce procedural times and improve quality of life (with the application of EQ-5D and KCCQ questionnaires).

This is a prospective, multicenter, parallel, open-label randomized controlled trial (RCT) with a 1:1 randomization including patients aged 18 years and older accepted for SAVR with or without concomitant CABG by the Heart Team at the St. Antonius Hospital Nieuwegein. All patients enrolled in the study will be randomized to additional pre-operative MSCT or no additional pre-operative MSCT. Postoperatively, a DW-MRI will be made in all patients. The trial will end after 30-day follow-up of all enrolled patients.

The main primary endpoint is the incidence of subclinical stroke rate (i.e., presence of new ischemic brain lesions) as identified with the use of DW-MRI made within one week postoperatively or before discharge. Secondary endpoints include the National Institutes of Health Stroke Scale (NIHSS) score within one week postoperatively (targeted at day two postoperatively), clinical ischemic stroke (conform VARC-3),transient ischemic attack diagnosed by a neurologist within one week postoperatively, defined by transient focal neurological signs or symptoms lasting < 24 h presumed to be due to focal brain, spinal cord or retinal ischemia, but without evidence of acute infarction by neuroimaging or pathology, or with no imaging performed (conform VARC-3), mortality at discharge (normally at three to five days postoperatively) or within one week postoperatively (if discharge is > 1 week postoperatively) and at three months postoperatively, the change in intervention strategy, the change in cannulation strategy, the change in clamping strategy, procedural times and the quality of life at three months postoperatively (assessed by EQ-5D and KCCQ)

When severe calcification of the ascending aorta is identified preoperatively on multi-slice computed tomography (MSCT), the operative strategy can be modified if necessary. This could possibly prevent stroke or even mortality in the study patients randomized to additional pre-operative MSCT. The MSCT will take 5-10 minutes. Only low-dose contrast-enhanced CT will be used, which results in a very low radiation risk. With application of too high dosages of contrast, there is a slight chance of kidney insufficiency. Furthermore, an allergic reaction to contrast could occur. However, patients with known allergies to contrast and patients with low renal function will be excluded from participation in this trial.

The patients receiving a preoperative CT-scan will have to be informed about all incidental findings found on the CT-scan. A possible disadvantage is found in the additional costs of a CT-scan, but the costs associated with stroke would outweigh the costs of a preoperative CT-scan. All patients will receive a DW-MRI before discharge. Contra-indications for MRI include pacemaker wires or implantable cardioverter defibrillators (ICDs), metallic implants, cochlear/ear implants, Swan-Ganz catheter, claustrophobia and contrast allergy. The presence of an aortic valve prosthesis is not a contra-indication for DW-MRI scanning.

All patients will be asked to fill out a questionnaire at baseline and within 90 days postoperatively. Since this will soon be implemented as part of standard care, the latter is not seen as extra burden for the patients.

Being tested
Preoperative CT
Medical subject headings
Aortic Valve Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Preoperative CTRadiation

    Preoperative contrast enhanced CT

Study groups in NCT06603454
Study groupRoleWhat they receive
Preoperative CTActive comparatorContrast-enhanced computed tomography of the aorta including the femoral arteries.
Receives: Radiation: Preoperative CT
No preoperative CTNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Subclinical stroke rate

    Subclinical stroke rate (i.e., presence of new ischemic brain lesions) as identified with the use of DW-MRI made within one week postoperatively or before discharge (in case of prolonged ICU stay).

    Measured: Within 90 days post procedure

Secondary outcomes (8)
  1. National Institutes of Health Stroke Scale

    National Institutes of Health Stroke Scale, ranging 0 - 42. Higher scores refer to a more severe stroke.

    Measured: within one week postoperatively (targeted at day two postoperatively)

  2. Clinical ischemic stroke (conform VARC-3)

    The incidence of clinical ischemic stroke (conform VARC-3) diagnosed by a neurologist within one week postoperatively, defined by the acute onset of focal neurological signs or symptoms conforming to a focal or multifocal vascular territory within the brain, spinal cord or retina and fulfilling one of the following criteria:

    • Signs or symptoms lasting ≥24 h or until death, with pathology or neuroimaging evidence of CNS infarction, or absence of other apparent causes
    • Symptoms lasting < 24 h, with pathology or neuroimaging evidence of CNS infarction in the corresponding vascular territory

    Measured: Within one week postoperatively

  3. TIA diagnosed by a neurologist

    The incidence of TIA diagnosed by a neurologist within one week postoperatively, defined by transient focal neurological signs or symptoms lasting < 24 h presumed to be due to focal brain, spinal cord or retinal ischemia, but without evidence of acute infarction by neuroimaging or pathology, or with no imaging performed (conform VARC-3).

    Measured: One week postoperatively

  4. Change in intervention strategy

    Change in intervention strategy (no unfavourable change, cancellation of surgery, switch to TAVR preprocedural, conversion from limited access to conventional full median sternotomy, conversion to TAVR)

    Measured: After hospital admission but before the end of surgery

  5. Change in cannulation strategy

    Change in cannulation strategy (no change, use of different cannula, avoiding cannulation of the ascending aorta/arch (thus femoral or subclavian cannulation), higher cannulation (arch), lower cannulation, echo-guided cannulation)

    Measured: During procedure

  6. Change in clamping strategy

    Change in clamping strategy (no change, change of clamping site, no clamping)

    Measured: During procedure

  7. Procedural times

    Implantation time (defined period from start of the first suture until the completion of the prosthesis implantation = fixation of last suture), surgical time, aortic cross-clamp (ACC) time, cardio-pulmonary bypass (CPB) time. All times in minutes.

    Measured: During procedure

  8. Quality of life at three months postoperatively (assessed by EQ-5D and KCCQ)

    All scores are represented on a 0-to-100-point scale. Higher score refers to preferabel outcomes.

    Measured: At baseline (prior to procedure) and 90 days post procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2024
  2. Study start4 Dec 2023
  3. Primary completion1 Apr 2025 (estimated)
  4. Study completion1 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
380 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06603454
Sponsor's protocol ID
NL77700.100.21
Acronym
GUIDE-SAVR
Status last verified
Sep 2024
First submitted
27 Jul 2024
Last updated
19 Sep 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: IPD data can be shared upon reasonable request to the corresponding author.

Questions about this trial

What is this clinical trial studying?

A study testing Preoperative CT in people with Aortic Valve Stenosis, run by Romy Hegeman at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Romy Hegeman, MD (+31 (0)6 41 71 16 79, r.hegeman@antoniusziekenhuis.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Subclinical stroke rate (time frame: Within 90 days post procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in